Bridge to Life has raised $110 million through a combination of Series C equity and debt financing to accelerate commercialization of its VitaSmart Hypothermic Oxygenated Perfusion System and advance its organ transplantation technology pipeline. New investor Soleus Capital led the equity financing alongside Lauxera Capital Partners and Bridge to Life directors, officers, and employees. Soleus Capital Credit Opportunities Fund provided the debt financing.
Bridge to Life plans to use the capital to expand its field organization and provide working capital to support deployment of VitaSmart across U.S. transplant centers. Funding will also support a proprietary organ viability assessment technology, expansion of the company’s organ preservation portfolio, and international growth.
A portion of the proceeds was used to refinance Bridge to Life’s existing credit facility with Perceptive Credit Funds, reducing outstanding leverage and lowering the company’s interest rate.
VitaSmart received FDA De Novo clearance in January 2026 and is the first and only hypothermic oxygenated perfusion system authorized by the FDA for liver transplantation.
Bridge to Life said adoption of VitaSmart has exceeded its expectations during the product’s first six months of commercialization. The company has established agreements with academic transplant centers, organ procurement organizations, and several high-volume liver transplant programs, while also reporting repeat orders and a pipeline of additional centers considering adoption.
The company is also developing a viability assessment tool designed to give transplant physicians more objective information for deciding whether donated organs should be accepted for transplantation. The investigational technology is not currently cleared for commercial sale.
Bridge to Life plans to expand its organ preservation and perfusion portfolio into additional organ applications over the next three years and is developing next-generation closed systems intended to simplify organ transport.
UBS Investment Bank served as exclusive financial advisor and placement agent, and Morgan Lewis & Bockius served as legal counsel.
KEY QUOTES:
“Bridge to Life is committed to improving transplant medicine through science-based solutions that bring more organs to more patients. This financing marks an important milestone for Bridge to Life and reflects the confidence our investors have in our technology, team, and long-term growth strategy. The VitaSmart launch has outpaced our expectations, as leading academic centers are adopting it rapidly. This financing enables us to meet that demand while advancing a pipeline that expands beyond liver transplantation to other solid organ transplants.”
Don Webber, CEO and President of Bridge to Life
“We led this financing because Bridge to Life pairs an established preservation franchise with a newly FDA-cleared perfusion platform that is already rapidly being adopted in the field, and with a credible pipeline behind it. This is a combination we believe is unmatched in the transplant category. We are excited to partner with Lauxera with whom we share a deep understanding of this market and conviction in Bridge to Life’s future potential.”
Ben Lund, Partner at Soleus Capital
“We have substantial experience investing in organ transplantation devices and we have seen firsthand how difficult it is to carry a preservation technology from clinical promise through to routine practice. Bridge to Life has done exactly that with a technology combining long-duration perfusions, class-leading ease of use, an accessible price point and outstanding clinical outcomes. These characteristics will accelerate machine perfusion adoption saving lives and reducing costs for the healthcare system.”
Samuel Levy, Co-Founding Partner at Lauxera Capital Partners
